Heritage Investors Management Corp Trims Position in Medtronic PLC $MDT

Heritage Investors Management Corp decreased its holdings in Medtronic PLC (NYSE:MDT) by 7.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,777 shares of the medical technology company’s stock after selling 5,103 shares during the quarter. Heritage Investors Management Corp’s holdings in Medtronic were worth $6,265,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Delos Wealth Advisors LLC bought a new position in Medtronic in the second quarter worth about $27,000. Corundum Trust Company INC purchased a new position in shares of Medtronic during the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. bought a new position in shares of Medtronic in the 3rd quarter worth approximately $29,000. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medtronic in the 3rd quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC purchased a new position in shares of Medtronic in the 3rd quarter valued at approximately $34,000. Institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MDT. Wells Fargo & Company initiated coverage on Medtronic in a report on Friday. They issued an “overweight” rating and a $114.00 price objective for the company. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Royal Bank Of Canada lifted their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a report on Wednesday, November 19th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Stock Down 0.3%

NYSE:MDT opened at $102.67 on Tuesday. The firm has a 50-day simple moving average of $99.59 and a two-hundred day simple moving average of $95.82. The firm has a market cap of $131.63 billion, a P/E ratio of 27.67, a P/E/G ratio of 2.71 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the company posted $1.26 earnings per share. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. Medtronic’s payout ratio is currently 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).